Summit Therapeutics earnings were -$240.8M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest SMMT earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$62.9M, up 2.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SMMT reported annual earnings of -$221.3M, with -64% growth.
Summit Therapeutics Earnings Reports & History FAQ
What were Summit Therapeutics's earnings last quarter?
On SMMT's earnings call on Invalid Date, Summit Therapeutics (NASDAQ: SMMT) reported Q1 2025 earnings per share (EPS) of -$0.00, up 0% year over year. Total SMMT earnings for the quarter were -$62.91 million. In the same quarter last year, Summit Therapeutics's earnings per share (EPS) was -$0.00.
Is Summit Therapeutics profitable or losing money?
As of the last Summit Therapeutics earnings report, Summit Therapeutics is currently losing money. Summit Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$240.76 million, a 107.5% increase year over year.
What was SMMT's earnings growth in the past year?
As of Summit Therapeutics's earnings date in Invalid Date, Summit Therapeutics's earnings has grown year over year. SMMT earnings in the past year totalled -$240.76 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.